αO-Conotoxin GeXIVA[1,2] Reduced Neuropathic Pain and Changed Gene Expression in Chronic Oxaliplatin-Induced Neuropathy Mice Model.

Authors:
Wang H; Li X; Qiao Y; Wang M; Wang W and 3 more

Journal:
Mar Drugs

Publication Year: 2024

DOI:
10.3390/md22010049

PMCID:
PMC10821445

PMID:
38276651

Journal Information

Full Title: Mar Drugs

Abbreviation: Mar Drugs

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"the rna sequencing raw data have been deposited in the gene expression omnibus--ncbi ( https://www ncbi nlm nih gov/geo/ ) with the accession number gse253183 (accessed on 18 january 2024)."

Code Sharing
Evidence found in paper:

"Conflicts of Interest Hainan University holds a patent for GeXIVA on which S.L., D.Z. and J.M.M. are inventors."

Evidence found in paper:

"This work was supported in part by the Major Intergovernmental Joint Research Project of National Key R & D Program of China (SQ2022YFE010956), Guangxi Science and Technology Base & Talents Fund (GUIKE AD22035948), Major International Joint Research Project of National Natural Science Foundation of China (82320108019), National Natural Science Foundation of China Grant 82360698 & 42376112, the 111 Project (D20010), and U.S. National Institutes of Health, grant number R35 GM136430, to J.M.M."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025